Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Breast cancer

2MO - Final analysis of the phase III randomized clinical trial, comparing HD201 vs referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting


03 Dec 2022


Mini Oral session: Breast cancer


Tumour Site

Breast Cancer


Xavier Pivot


Annals of Oncology (2022) 33 (suppl_9): S1431-S1435. 10.1016/annonc/annonc1118


X. Pivot1, A. Manikhas2, V. Shamrai3, G. Dzagnidze4, H.H.F. Soo5, V. Kaewkangsadan6, F. Petrelli7, C. Villanueva8, J. Kim9, S. Pradhan9, L. Jaison9, P. Feyaerts9, L. Kaufman10, M. Derde11, F. Deforce12, D. Cox13

Author affiliations

  • 1 Medical Oncology Dept., ICANS - Institut de Cancérologie Strasbourg Europe, 67200 - Strasbourg/FR
  • 2 Clinical Oncology, City Clinical Oncological Dispensary, 198255 - Saint-Petersburg/RU
  • 3 Clinical Oncology, Vinnytsia Regional Clinical Oncological Dispensary, 21029 - Vinnytsia/UA
  • 4 Breast Unit, S. Khechinashvili University Hospital, 179 - Tbilisi/GE
  • 5 Clinical Oncology, Penang General Hospital, 10990 - Pulau Penang/MY
  • 6 Department Of Surgery, Phramongkutklao Hospital, 10400 - Bangkok/TH
  • 7 Oncology Unit, ASST Bergamo ovest, 24047 - Treviglio BG/IT
  • 8 Medical Oncology, Centre de Cancérologie du Grand Montpellier (CCGM), 34070 - Montpellier/FR
  • 9 Medical & Regulatory Affairs, Prestige Biopharma Limited, 138567 - Singapore/SG
  • 10 Biostatistics, DICE NV, 1702 - Groot-Bijgaarden/BE
  • 11 Biometrics, DICE NV, 1702 - Groot-Bijgaarden/BE
  • 12 Ceo, DICE NV, 1702 - Groot-Bijgaarden/BE
  • 13 Inserm U1113, INSERM U1113, 67200 - Strasbourg/FR


Login to access the resources on OncologyPRO.

Abstract 2MO


TROIKA trial previously demonstrated equivalence in terms of total pathological complete response (pCR) after neoadjuvant treatment between HD201 and referent trastuzumab. All secondary objectives and secondary endpoints were in line with the result of the primary endpoint. The objective was to compare survival outcomes and safety in patients treated by HD201 or referent trastuzumab in the TROIKA trial.


This study included 502 patients with ERBB2-positive early breast cancer treated with either HD201 or referent trastuzumab, across 70 centers in 12 countries in Western and Eastern Europe and Asia. This analysis was performed after all patients completed the study, at a median follow up of 37.7 months (Q1-Q3, 37.3-38.1 months). Eligible patients received 4 cycles of docetaxel, 75 mg/m2, followed by 4 cycles of epirubicin, 75 mg/m2, and cyclophosphamide, 500 mg/m2 with either HD201 or referent trastuzumab (loading dose, 8 mg/kg; maintenance dose, 6 mg/kg) every 3 weeks in the neoadjuvant setting and then, 10 cycles of HD201 or referent trastuzumab after surgery, according to their initial randomization. Event-free survival (EFS) and overall survival (OS) rates were calculated using the Kaplan-Meier method. Hazard ratios (HR) were estimated by Cox proportional hazards regression. Adverse events (AEs) were graded per standard criteria.


A total of 474 (94.2%) patients were eligible for inclusion in the per-protocol set. In this population, the 3-year EFS rates were 85.6% (95%CI: 80.28 - 89.52) and 84.9% (95%CI: 79.54 - 88.88) in HD201 and referent trastuzumab groups, respectively (Log rank p = 0.938) (HR 1.02, 95%CI: 0.63 - 1.63; p = 0.945). The 3-year OS rates were comparable for HD201 (95.6%; 95%CI: 91.90 - 97.59) and referent trastuzumab treatment groups (96.0%, 95%CI: 92.45 - 97.90) (log rank p = 0.606). During the post-treatment follow up period, AEs were reported for 64 (27.4%) and 72 (29.8%) patients in the HD201 and the referent trastuzumab groups respectively and no serious event was related to study treatment.


This final analysis of the TROIKA trial further confirms the comparable efficacy and safety of HD201 and referent trastuzumab.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Prestige Biopharma Limited.


Prestige Biopharma Limited.


J. Kim, S. Pradhan, L. Jaison, P. Feyaerts: Financial Interests, Institutional, Full or part-time Employment: Prestige Biopharma Limited. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.